Journal of Experimental & Clinical Cancer Research (Jul 2019)

PTBP3 contributes to colorectal cancer growth and metastasis via translational activation of HIF-1α

  • Pingfu Hou,
  • Fang Chen,
  • Hongmei Yong,
  • Tian Lin,
  • Jingjing Li,
  • Yu Pan,
  • Tao Jiang,
  • Minle Li,
  • Yansu Chen,
  • Jun Song,
  • Junnian Zheng,
  • Jin Bai

DOI
https://doi.org/10.1186/s13046-019-1312-y
Journal volume & issue
Vol. 38, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Colorectal cancer (CRC) remains the fourth most common cause of cancer-related mortality worldwide. We aimed to identify key molecules and signalling pathways mediating CRC growth and metastasis. Polypyrimidine tract-binding protein 3 (PTBP3) is a member of PTB family. A prooncogenic role for PTBP3 has also been discovered in several kinds of tumors. However, the expression and biological functions of the PTBP3 are still unknown in CRC. Methods We analysed the expression levels of PTBP3 using tissue microarray containing 568 CRC tissues and corresponding non-tumor adjacent tissues. The correlations between the PTBP3 expression level and clinicopathological features were evaluated using the chi-square test. The functional characterization for the role and molecular mechanism of PTBP3 in CRC was investigated through a series of in vitro and in vivo experiments. Results We showed that PTBP3 expression was increased in human CRC, and high PTBP3 expression was correlated with poor five-year overall survival and disease-free survival. Moreover, PTBP3 promoted tumor cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo. PTBP3 enhanced HIF-1α protein expression by directly binding to the 5′UTR HIF-1α mRNA and activated translation of HIF-1α. Furthermore, HIF-1α was responsible for PTBP3-induced cell migration and invasion. Conclusions PTBP3 appears to be a novel oncogene of CRC through binding to the IRES region of HIF-1α mRNA, which regulates HIF-1α translation. PTBP3 can serve as a promising predictive biomarker for recurrence and prognosis in patients with CRC.

Keywords